Synapse - Works

Results (4640)

Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors

Meeting Abstract

Bendell, J. C.; Strauss, J. F.; Fakih, M.; McRee, A. J.; Hendifar, A. E.; Rosen, L. S.; Cercek, A.; Rowinsky, E. K.; Szarek, M.; Gonsalves, F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study

Meeting Abstract

Aguado, E.; Abou-Alfa, G. K.; Zhu, A. X.; Macarulla, T.; Fan, B.; Nejad, P.; Choe, S.; Jiang, L. W.; Gliser, C.; Pandya, S. S.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Meeting Abstract

Moehler, M.; Shitara, K.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Campos Bragagnoli, A.; Liu, T.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Real-world treatment patterns and effectiveness of liposomal irinotecan in a NAPOLI1-based regimen among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): A multi-academic center chart review

Meeting Abstract

Yu, K. H.; Hendifar, A.; Alese, O.; Draper, A.; Abdelrahim, M.; Burns, E.; Khan, G.; Cockrum, P.; Bhak, R.; Nguyen, C.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial

Meeting Abstract

Hochhauser, D.; Kindler, H.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Arnold, D.; Oh, D. Y.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03)

Meeting Abstract

Janjigian, Y. Y.; Viglianti, N.; Liu, F.; Mendoza-Naranjo, A.; Puvvada, S.
Annals of Oncology (2020)

Fulltext@MSK | Save

PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with FGFR2 gene rearrangements

Meeting Abstract

Abou-Alfa, G. K.; Borbath, I.; Cohn, A. L.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D. Y.; Roychowdhury, S.; Sadeghi, S.; Shroff, R. T.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

Meeting Abstract

Ku, G.; Bendell, J. C.; Tolcher, A. W.; Hurvitz, S. A.; Krishnamurthy, A.; El-Khoueiry, A. B.; Patnaik, A.; Shroff, R. T.; Noonan, A.; Hahn, N. M.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save

MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer

Meeting Abstract

Strickler, J.; Ng, K.; Cercek, A.; Fountzilas, C.; Sanchez, F.; Hubbard, J.; Wu, C.; Stecher, M.; Walker, L. N.; Bekaii-Saab, T.
Annals of Oncology (2020)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study

Meeting Abstract

André, T.; Amonkar, M.; Norquist, J.; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C. J.; Smith, D.; Garcia-Carbonero, R.; more...
Annals of Oncology (2020)

Fulltext@MSK | Save